Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Investment Securities (2016 - 2025)

Ani Pharmaceuticals' Gains from Investment Securities history spans 16 years, with the latest figure at $6.9 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 29.72% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $6.6 million, up 24.2%, while the annual FY2025 figure was $6.6 million, 24.2% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $6.9 million at Ani Pharmaceuticals, up from -$295000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.9 million in Q4 2025 and bottomed at -$5.3 million in Q3 2024.
  • The 5-year median for Gains from Investment Securities is $620000.0 (2021), against an average of $1.7 million.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 11000.0% in 2021 before it crashed 218.85% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $463000.0 in 2021, then surged by 434.77% to $2.5 million in 2022, then plummeted by 91.28% to $216000.0 in 2023, then surged by 2375.46% to $5.3 million in 2024, then grew by 29.72% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Gains from Investment Securities are $6.9 million (Q4 2025), -$295000.0 (Q3 2025), and $5.3 million (Q4 2024).